-
EP4340877
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4340877
| EP4340877 - USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 23.02.2024 Database last updated on 08.04.2026 | |
| Former | The international publication has been made Status updated on 26.11.2022 | Most recent event Tooltip | 02.04.2026 | Supplementary search report | published on 29.04.2026 [2026/18] | Applicant(s) | For all designated states RemeGen Co., Ltd. No. 58 Beijing Middle Road Yantai Development Zone Yantai District China (Shandong) Pilot Free Trade Zone Yantai, Shandong 264006 / CN | [2024/13] | Inventor(s) | 01 /
FANG, Jianmin Beijing Middle Road, Yantai Development Zone Yantai District, China (Shandong) Pilot Free Trade Zone Yantai, Shandong 264006 / CN | 02 /
JIANG, Jing Beijing Middle Road, Yantai Development Zone Yantai District, China (Shandong) Pilot Free Trade Zone Yantai, Shandong 264006 / CN | 03 /
LI, Shenjun Beijing Middle Road, Yantai Development Zone Yantai District, China (Shandong) Pilot Free Trade Zone Yantai, Shandong 264006 / CN | 04 /
SU, Xiaohong Beijing Middle Road, Yantai Development Zone Yantai District, China (Shandong) Pilot Free Trade Zone Yantai, Shandong 264006 / CN | [2024/13] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2024/13] | Application number, filing date | 22804012.7 | 18.05.2022 | [2024/13] | WO2022CN93631 | Priority number, date | CN202110559728 | 21.05.2021 Original published format: CN202110559728 | [2024/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022242692 | Date: | 24.11.2022 | Language: | EN | [2022/47] | Type: | A1 Application with search report | No.: | EP4340877 | Date: | 27.03.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.11.2022 takes the place of the publication of the European patent application. | [2024/13] | Search report(s) | International search report - published on: | CN | 24.11.2022 | (Supplementary) European search report - dispatched on: | EP | 01.04.2026 | Classification | IPC: | A61K47/68, A61K39/395, A61K45/00, A61K35/00, A61P43/00, A61P35/00, C07K16/28, C07K16/32 | [2026/18] | CPC: |
A61P43/00 (EP,IL,US);
A61K45/06 (IL);
A61K47/6851 (KR,US);
A61K47/6889 (EP,IL,KR,US);
A61K39/395 (KR);
A61K39/3955 (US);
A61K47/68 (EP);
A61K47/68031 (EP,IL,KR,US);
A61K47/6855 (EP,IL);
A61P35/00 (EP,IL,KR,US);
C07K16/2827 (EP,IL,KR);
C07K16/32 (EP,IL,KR);
| C-Set: |
A61K47/68, A61K2300/00 (EP);
A61K2300/00, A61K47/68 (EP) |
| Former IPC [2024/13] | A61K39/395, A61K45/00, A61K47/20, A61K35/00, A61P43/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/13] | Validation states | MA | 13.11.2023 | Title | German: | VERWENDUNG EINES ANTIKÖRPER-WIRKSTOFF-KONJUGATS IN KOMBINATION MIT EINEM IMMUNCHECKPOINT-INHIBITOR BEI DER BEHANDLUNG VON UROTHELKARZINOM | [2024/13] | English: | USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER | [2024/13] | French: | UTILISATION D'UN CONJUGUÉ ANTICORPS-MÉDICAMENT EN COMBINAISON AVEC UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE DANS LE TRAITEMENT DU CANCER UROTHÉLIAL | [2024/13] | Entry into regional phase | 13.11.2023 | National basic fee paid | 13.11.2023 | Search fee paid | 13.11.2023 | Designation fee(s) paid | 13.11.2023 | Examination fee paid | Examination procedure | 13.11.2023 | Examination requested [2024/13] | 18.06.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.05.2024 | Renewal fee patent year 03 | 09.05.2025 | Renewal fee patent year 04 | 24.03.2026 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] ZHOU LI ET AL: "RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.", JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 15_suppl, 20 May 2021 (2021-05-20), United States, pages 4534 - 4534, XP093379700, ISSN: 0732-183X, DOI: 10.1200/JCO.2021.39.15_suppl.4534 [X] 1-15 * abstract *[I] 1-15 DOI: http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4534 | [Y] SHENG XINAN ET AL: "An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).", JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 15_suppl, 20 May 2021 (2021-05-20), pages 4584 - 45844, XP093379727, DOI: 10.1200/JCO.2021.39.15_suppl.4584 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4584 | [Y] XUEJING YAO ET AL: "A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity", BREAST CANCER RESEARCH AND TREATMENT, vol. 153, no. 1, 8 August 2015 (2015-08-08), New York, pages 123 - 133, XP055370764, ISSN: 0167-6806, DOI: 10.1007/s10549-015-3503-3 [Y] 1-15 * the whole document * * figure -; compound - * DOI: http://dx.doi.org/10.1007/s10549-015-3503-3 | International search | [XY] CN110049779 (DAIICHI SANKYO CO LTD et al.) [X] 34 * claims 1-92 *[Y] 1-32、36 | [XY] WO2020042941 (REMEGEN LTD et al.) [X] 33-35 * claims 1-18 *[Y] 1-32，36 | [Y] US2021101888 (PAZOLLI ERMIRA et al.) [Y] 1-36 * description， paragraphs 1046-1064 * | [Y] US2021093730 (SPERBER THORSTEN RJ et al.) [Y] 1-36 * description， paragraphs 105-109 * | [A] US2021101982 (KWAN BYRON HUA et al.) [A] 1-36 * the whole document * | [A] US2018110772 (GOVINDAN SERENGULAM V et al.) [A] 1-36 * the whole document * | [A] WO2021086981 (CSPC DOPHEN CORP et al.) [A] 1-36 * the whole document * | [A] US2018271996 (BODYAK NATALYA D et al.) [A] 1-36 * the whole document * | [Y] LATTANZI MICHAEL, ROSENBERG JONATHAN E.: "The emerging role of antibody-drug conjugates in urothelial carcinoma", EXPERT REVIEW OF ANTICANCER THERAPY, EXPERT REVIEWS LTD., GB, vol. 20, no. 7, 31 July 2020 (2020-07-31), GB , pages 551 - 561, XP009541182, ISSN: 1473-7140, DOI: 10.1080/14737140.2020.1782201 [Y] 1-36 * pages 551-561 * DOI: http://dx.doi.org/10.1080/14737140.2020.1782201 | [A] SHENG XINAN, YAN XIEQIAO, WANG LIN, SHI YANXIA, YAO XIN, LUO HONG, SHI BENKANG, LIU JIYAN, HE ZHISONG, YU GUOHUA, YING JIANMING, H: "Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting AntibodyDrug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 27, no. 1, 1 January 2021 (2021-01-01), US, pages 43 - 51, XP093006324, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-20-2488 [A] 1-36 * pages 43-51 * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-20-2488 | [A] GUO LEI, CHENG SI-QI;LI JIA-MIN: "Global approved new drugs in 2019: reported and prospect", JOURNAL OF MULTIDISCIPLINARY CANCER MANAGEMENT(ELECTRONIC VERSION), vol. 6, no. 1, 30 January 2020 (2020-01-30), pages 70 - 79, XP093006321, DOI: 10.12151/JMCM.2020.01-09 [A] 1-36 * pages 70-79 * DOI: http://dx.doi.org/10.12151/JMCM.2020.01-09 |